- Home
- AKRO
as 09-05-2025 12:30pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.9B | IPO Year: | 2019 |
| Target Price: | $80.38 | AVG Volume (30 days): | 856.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.34 - $58.40 | Next Earning Date: | 08-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Jonathan | AKRO | Chief Operating Officer | Sep 2 '25 | Sell | $46.83 | 12,500 | $576,035.08 | 197,484 | |
| Young Jonathan | AKRO | Chief Operating Officer | Aug 12 '25 | Sell | $48.02 | 12,500 | $597,325.95 | 197,484 | |
| Henderson Jane | AKRO | N/A | Aug 12 '25 | Sell | $47.46 | 3,000 | $142,371.00 | 9,398 | |
| Cheng Andrew | AKRO | President and CEO | Aug 11 '25 | Sell | $48.79 | 30,000 | $1,457,595.98 | 491,157 | |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | Jun 20 '25 | Sell | $54.59 | 875 | $47,766.25 | 31,698 | |
| White William Richard | AKRO | Chief Financial Officer | Jun 18 '25 | Sell | $54.84 | 1,634 | $89,608.56 | 57,521 | |
| Yale Catriona | AKRO | Chief Development Officer | Jun 18 '25 | Sell | $54.84 | 1,633 | $89,553.72 | 90,598 | |
| Young Jonathan | AKRO | Chief Operating Officer | Jun 18 '25 | Sell | $54.84 | 1,453 | $79,682.52 | 197,484 | |
| Gangloff Scott A. | AKRO | Chief Technology Officer | Jun 18 '25 | Sell | $54.84 | 848 | $46,504.32 | 23,452 | |
| Yale Catriona | AKRO | Chief Development Officer | Jun 16 '25 | Sell | $54.70 | 10,000 | $542,306.41 | 90,598 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Akero Therapeutics Insider Sold Shares Worth $542,306, According to a Recent SEC Filing
MT Newswires
3 months ago
Akero Therapeutics Insider Sold Shares Worth $2,044,940, According to a Recent SEC Filing
GlobeNewswire
3 months ago
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
3 months ago
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Insider Monkey
4 months ago
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
MT Newswires
4 months ago
Akero Therapeutics Insider Sold Shares Worth $1,244,455, According to a Recent SEC Filing
MT Newswires
4 months ago
Akero Therapeutics Q1 Net Loss Unchanged
Insider Monkey
4 months ago
Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.